Literature DB >> 6950170

Growth and characterization of childhood rhabdomyosarcomas as xenografts.

J A Houghton, P J Houghton, B L Webber.   

Abstract

Eleven surgical specimens of childhood rhabdomyosarcoma (RMS), two bone marrow samples, and cells from ascitic fluid from 1 patient were implanted sc into immune-deprived inbred CBA/CaJ mice. From these, seven lines of RMS were obtained as xenografts, each retaining the histologic characteristics of the tumor of origin and human lactate dehydrogenase isozymes; these represented 6 of the 11 surgical specimens, whereas one line originated from the transplanted cells from ascitic fluid. It was concluded that children RMS has a fairly high frequency of heterotransplantability in this system and that such a laboratory model may prove useful in the development of new therapeutic regimens in this disease.

Entities:  

Mesh:

Year:  1982        PMID: 6950170

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  19 in total

Review 1.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

2.  Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Authors:  Brendan Murphy; Han Yin; John M Maris; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Stephen T Keir; Raushan T Kurmasheva; Igor Dvorchik; Jianrong Wu; Catherine A Billups; Nana Boateng; Malcolm A Smith; Richard B Lock; Peter J Houghton
Journal:  Cancer Res       Date:  2016-08-05       Impact factor: 12.701

3.  FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.

Authors:  Mamata Singh; Justin M Leasure; Christopher Chronowski; Brian Geier; Kathryn Bondra; Wenrui Duan; Lauren A Hensley; Miguel Villalona-Calero; Ning Li; Anthony M Vergis; Raushan T Kurmasheva; Changxian Shen; Gary Woods; Nikhil Sebastian; Denise Fabian; Rita Kaplon; Sue Hammond; Kamalakannan Palanichamy; Arnab Chakravarti; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2014-04-30       Impact factor: 12.531

4.  Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.

Authors:  P J Houghton; J A Houghton; L Myers; P Cheshire; J J Howbert; G B Grindey
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Authors:  H S Friedman; P J Houghton; S C Schold; S Keir; D D Bigner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.

Authors:  T P Brent; P J Houghton; J A Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

7.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.

Authors:  P J Houghton; P J Cheshire; L Myers; C F Stewart; T W Synold; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.

Authors:  P J Houghton; P J Cheshire; J C Hallman; J L Gross; R J McRipley; J H Sun; C H Behrens; D L Dexter; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Evaluation of 3-(p-fluorophenyl)-L-alanyl-3-[m-bis-(2-chloroethyl) aminophenyl]-L-alanyl-L-methionine ethyl ester HCl (PTT.119) against xenografts of human rhabdomyosarcoma.

Authors:  P J Houghton; R Tharp; J A Houghton; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.

Authors:  P J Houghton; P J Cheshire; J D Hallman; L Lutz; H S Friedman; M K Danks; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.